Bayer HealthCare has announced strong growth for 2014, assisting the Bayer group in achieving record sales and earnings for the year.
The company’s sales total came to 42.24 billion euros (£30.73bn), up by 5.2% year on year. The HealthCare division contributed 19.98 billion euros to this total.
In the HealthCare subgroup, business expanded by 5.6% compared to 2013. This was primarily due to double-digit growth for the pharmaceuticals division, driven by strong sales of the recently-launched brands Xarelto, Eylea, Stivarga, Xofigo and Adempas.
Management board chairman Dr Marijn Dekkers said: “These products have played a crucial role in making us one of the fastest-growing large companies in the pharmaceutical industry.”
Bayer’s consumer health business also showed good impetus, giving the company confidence to deliver on its strategy of becoming an entirely life science-focused organisation.
